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A b s t r A c t
We present a case of repeat successful ventricular tachycardia ablation in an elderly 
frail post-myocardial infarction patient who presented with recurrent and often inces-
sant episodes of slow ventricular tachycardia. An 85-year old thin male fitted with an 
implantable cardioverter defibrillator (ICD) device presented with a hemodynami-
cally stable, slow ventricular tachycardia, temporarily terminated after multiple anti-
tachycardia pacing attempts. A previous recent ventricular tachycardia ablation pro-
cedure due to multiple ICD activations yielded poor result. Identification and elimi-
nation of late potentials was accompanied by final non-inducibility and a free from 
ventricular tachycardia mid-term outcome.
I N t r O D U c t I O N
Ventricular tachycardia (VT) is an important cause of morbidity and mortality in 
patients with a previous myocardial infarction. Electrical storm is a life-threatening 
arrhythmia complication affecting patients treated with an implantable cardioverter 
defibrillator (ICD).1 ICDs are currently the mainstay of treatment for patients with 
ischemic cardiomyopathy or non-ischemic cardiomyopathy, who are at risk for sudden 
cardiac death due to VT.2 However, ICDs effectively terminate VT, but do not prevent 
VT episodes. Defibrillator shocks increase mortality and worsen quality of life.3 Anti-
arrhythmic combined therapy of beta-blocker and amiodarone reduces ICD shocks in 
a significant proportion of patients; however, amiodarone has significant side effects, 
resulting in drug discontinuation in nearly 25% of the patients.4
Catheter ablation of VT has made significant strides over the recent years with 
new evidence from prospective randomized trials on outcome in patients with ischemic 
heart disease.5-7 The role of catheter ablation is extremely important especially in order 
to control incessant VT and to reduce or prevent recurrent episodes of sustained VT.5 
In the present manuscript, we present a case of repeat successful VT ablation in an 
elderly frail post-myocardial infarction patient who presented with recurrent and often 
incessant episodes of slow VT.
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c A s e  r e p O r t
An 85-year old thin male (body mass index <20 kg/m2) was 
admitted to our department due to dizziness and palpitations 
caused by an incessant, though hemodynamically stable, slow 
ventricular tachycardia (VT) with blood pressure of 85/50 
mmHg and heart rate of 145 bpm. VT was detected by his 
dual-chamber ICD (VT zone between 140 and 200 bpm and 
VF zone >200 bpm) but only temporarily terminated after 
multiple anti-tachycardia pacing attempts. Bolus and subse-
quent loading dose of intravenous amiodarone suppressed the 
incessant VT. Laboratory examination was unremarkable for 
abnormal findings.
Our patient had suffered from an inferior wall myocardial 
infarction treated conservatively 20 years earlier. He had also 
had a history of dual-chamber pacemaker implantation 14 
years ago due to sick sinus syndrome. His pacing system was 
upgraded to ICD 7 years later after a clinical episode of VT. 
At that time and thereafter serial transthoracic echocardio-
grams revealed the presence of mild systolic dysfunction (left 
ventricular ejection fraction ~45-50%) with postero-inferior 
wall akinesia. He reported numerous appropriate ICD activa-
tions during the last 7 years, treated initially with metoprolol 
and amiodarone. He was in chronic atrial fibrillation and had 
only exertional dyspnea (New York Heart Association class 
II). Seven months prior to admission, the patient underwent 
VT ablation due to recurrent VT episodes despite the ad-
ministration of combined anti-arrhythmic therapy. Based on 
the report of the initial procedure, induced VT was ablated 
during activation mapping. No VT was inducible after the final 
programmed ventricular stimulation with up to 3 extrastimuli 
delivered at the right ventricular apex. The patient was dis-
charged on mexiletine instead of amiodarone due to imaging 
findings suggestive of pulmonary fibrosis. His post-procedural 
course was characterized by 42 episodes of silent termination 
of recurrent slow VT until this episode of incessant slow VT 
occurred.
Despite the initial VT suppression after amiodarone ad-
ministration, the old age and the frail condition of our patient 
(based on the low body mass index), it was decided to proceed 
with a repeat ablation procedure aiming to discontinue the pre-
carious use of amiodarone (prior history of possible pulmonary 
toxicity). The procedure was performed under mild sedation 
with continuous monitoring of invasive arterial pressure.
A 3.5-mm distal-tip irrigated catheter (Navistar Thermo-
cool SF, bidirectional D-F, Biosense Webster Inc, Diegem, 
Belgium) served as the mapping catheter using the retrograde 
transaortic approach. High-density substrate mapping with 
a fill threshold of 5 mm in low voltage areas (LVA) and 10 
mm elsewhere was performed using the Carto® 3 workstation 
(Biosense Webster, Diamond Bar, California, USA). LV 
endocardial bipolar dense scar was defined as an area with a 
bipolar voltage of ≤0.5 mV and areas with a bipolar voltage 
>0.5 mV and <1.5 mV were defined as bipolar border zone. 
Scar was present in the basal part of the infero-postero-lateral 
wall (Fig. 1).
A color-coded map of sinus rhythm activation delay was 
drawn on the same anatomical shell by manual tagging the end 
of all electrograms (Late Potentials - LPs map). The definition 
of LPs included either continuous fragmented activity bridging 
from the main component within the QRS to the latest signal 
recorded outside the QRS (fractionated LPs), or isolated 
potentials recorded after the QRS offset (isolated LPs); the 
annotation on the mapping system was always taken at the 
latest recorded activity. LPs were present also in the basal part 
of the infero-postero-lateral wall (Fig. 1).
During high-density substrate mapping, the clinical VT 
was mechanically provoked while moving the catheter (cycle 
length 500 ms, monophasic R V1-3, transition zone in V4, rS 
in I, aVL, QS in II, qr in III, aVF) (Fig. 2). VT was ablated 
using activation mapping and directly terminated in the basal 
part of the posterior wall (Fig. 3). Pace-mapping maneuver at 
the termination site also revealed a nearly perfect matching 
with the clinical VT (Fig. 4). Ablation continued in sponta-
neous rhythm aiming at the complete abolition of LPs with a 
power setting of 30–35 Watts and a temperature limit of 43°C. 
Remapping documented the absence of LPs after ablation. 
Programmed ventricular stimulation with up to 3 extrastimuli 
from the right ventricular apex was performed without induc-
ing any VT (Fig. 5).
The procedure was completed uneventfully and the patient 
was discharged home 48 hours later. Amiodarone was discon-
tinued 1 month later. The patient remains asymptomatic and 
in good clinical condition without ICD activation after a short 
follow-up period of 10 months.
D I s c U s s I O N
Selection of catheter ablation for an individual patient 
should consider risks and benefits that are determined by 
patient characteristics, as well as the availability of appropri-
ate facilities with technical expertise. In patients with struc-
tural heart disease, episodes of sustained VT are a marker of 
increased mortality and reduced quality of life in those who 
have ICDs.1,3,5 Anti-arrhythmic medications can reduce the 
frequency of ICD therapies, but have modest efficacy and 
side effects.4,5 Advances in technology and understanding of 
VT substrates now allow ablation of multiple and unstable 
VTs with acceptable safety and efficacy, even in patients with 
advanced heart disease.8 It has also been reported that catheter 
ablation within a dedicated VT unit, prevents long-term VT 
recurrences and may favorably affect survival in structural 
heart disease patients who have VT.8
Inducibility of sustained monomorphic VT is considered 
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FIgUre 1. Isolated late potential recorded after the QRS offset (A). Endocardial bipolar dense scar was defined as an area with a 
bipolar voltage of ≤0.5 mV and areas with a bipolar voltage >0.5 mV and <1.5 mV were defined as bipolar border zone. Scar was 
present in the basal part of the infero-postero-lateral wall (b). Fractionated and isolated late potentials recorded after the QRS off-
set, annotated on the mapping system during sinus rhythm, were also present within the scar in the basal part of the infero-postero-
lateral wall (c).
FIgUre 2. Twelve lead ECG of the clinical and spontaneously induced ventricular tachycardia.
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FIgUre 3. Ventricular tachycardia was ablated during activation mapping and directly terminated in the basal part of the posterior 
wall.
FIgUre 4. Pace-mapping maneuver at the termination site, where late potential was present, also revealed a nearly perfect matching 
with the clinical ventricular tachycardia.
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as a marker for arrhythmogenic substrate and possible VT 
recurrence and therefore it is still used as an indispensable 
procedural endpoint.5,8 Because VT inducibility testing is 
hampered by unsatisfactory reproducibility and in some cases 
by non-inducibility, a strategy aiming to abolish all potential 
circuits is additive. Additionally, mapping and ablating during 
sinus rhythm improves hemodynamic stability, especially when 
faced with patients who have poorly tolerated VT, several VTs, 
VTs with rapidly changing morphologies, polymorphic VT/
VF or VTs that are difficult to terminate within a reasonable 
timeframe.
Other strategies for VT ablation in sinus rhythm include 
scar-based ablation using linear or encircling lesions to divide 
the VT reentry isthmus.9,10 Isolated LP and conducting chan-
nels in sinus rhythm have been shown to correlate with VT 
circuit isthmuses and can thus be used as a target for substrate 
ablation in sinus rhythm.11,12 It has been demonstrated that 
successful LP abolition reduces VT recurrence and can be 
systematically instituted as a second procedural endpoint in 
structural VT ablation procedures.13 This endpoint can be 
clearly defined by systematically remapping and document-
ing the presence or absence of LP after ablation, with further 
ablation if necessary and feasible.
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